Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | QDPR | P09417 | 2/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17669255 | 1.00 | MAOB (0.41) | MAOBQDPRACMSDMAOACES2 | |
| SCHEMBL18559476 | 0.89 | ESR2 (0.42) | MAOBQDPRACMSDMAOA | |
| SCHEMBL28400897 | 0.89 | PRKAB2 (0.43) | MAOB | |
| SCHEMBL10783589 | 0.87 | CYP2C9 (0.53) | MAOBMAOA | |
| SCHEMBL29210599 | 0.85 | MAOB (0.38) | MAOBMAOACES2CES1 | |
| SCHEMBL10951397 | 0.85 | CYP2C9 (0.45) | MAOB | |
| SCHEMBL10780906 | 0.84 | CYP2C9 (0.44) | — | |
| SCHEMBL10408450 | 0.84 | CYP2C9 (0.50) | MAOBMAOA | |
| SCHEMBL10408453 | 0.84 | CYP2C9 (0.50) | MAOBMAOA | |
| SCHEMBL10408452 | 0.84 | CYP2C9 (0.50) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076941-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | UNIV GEORGETOWN (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4688785-A1 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | Beone Medicines I GmbH (CH) | 2026-02-11 | — | — | EP | disclosed |
| EP-4658655-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024199255-A1 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-d] PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024160278-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
| CN-117177970-A | Polycyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2022228490-A1 | POLYCYCLIC DERIVATIVE MODULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076941-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | FLI1, EWSR1, HNRNPH3 | MAOB 3282/4885QDPR 4794/4885ACMSD 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.